Abstract: Type 2 Diabetes Mellitus (T2DM) is a chronic condition frequently accompanied by comorbidities such as hypertension, obesity, and dyslipidemia, increasing the risk of severe complications.
Silence Therapeutics advanced its RNAi drug for polycythemia vera, shared new Phase 2 trial updates, and reaffirmed a strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback